Excipients are no longer passive ingredients—they’re critical to the success of precision drug delivery systems. In this whitepaper, Ardena shares insights into the development and GMP manufacturing of two novel phospholipids used in nanomedicine applications, including oncology and thermosensitive liposomes.
Gain a deeper understanding of:
– Control strategies for novel excipients
– Overcoming analytical and scalability challenges
– The regulatory implications of excipient innovation
Read the full whitepaper.
Thank you for your interest in our scientific content.
